Signalling paediatric side effects using an ensemble of simple study designs

Drug Safety

Volumn 37, Issue 3, 2014, Pages 163-170

  Reps, Jenna M ^a   Garibaldi, Jonathan M ^a   Aickelin, Uwe ^a   Soria, Daniele ^a   Gibson, Jack E ^b   Hubbard, Richard B ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Community Health Sciences Clinical Sciences Building ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN DERIVATIVE; PENICILLIN G SODIUM; PENICILLIN V;

ADVERSE DRUG REACTION; ARTICLE; CHILD; CLASSIFIER; CONCEPTUAL FRAMEWORK; DRUG SURVEILLANCE PROGRAM; GROUPS BY AGE; HUMAN; LONGITUDINAL STUDY; PRIORITY JOURNAL; RANDOM FOREST; REFERENCE VALUE; RISK ASSESSMENT; STUDY DESIGN; UNSPECIFIED SIDE EFFECT; EPIDEMIOLOGY; FACTUAL DATABASE; METHODOLOGY; OFF LABEL DRUG USE; STATISTICAL MODEL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CAUSALITY; CHILD; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MODELS, STATISTICAL; OFF-LABEL USE; RESEARCH DESIGN;

EID: 84896067928     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0137-z     Document Type: Article

References (21)

1. Aagaard L, Christensen A, Hansen EH. Information about adverse drug reactions reported in children: a qualitative review of empirical studies. Br J Clin Pharmacol. 2010;70(4):481-91.
2. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C, Seyberth H, Pandolfini C, Raffaelli MP, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. Br Med J. 2000;320(7227):79-82. (Pubitemid 30173044)
3. Rose K, van den Anker JN. Guide to paediatric drug development and clinical research. Basel: Karger; 2010.
4. Bwakura-Dangarembizi M, Musesengwa R, Nathoo KJ, Takaidza P, Mhute T, Vhembo T. Ethical and legal constraints to childrens participation in research in Zimbabwe: experiences from the multicenter pediatric HIV ARROW trial. BioMed Central Med Ethics. 2012;13(1):17.
5. Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet. 2004;364(9436):803-11. (Pubitemid 39165102)
6. Lidz CW, Appelbaum PS, Grisso T, Renaud M. Therapeutic misconception and the appreciation of risks in clinical trials. Soc Sci Med. 2004;58(9):1689-97. (Pubitemid 38281135)
7. Avery A, Anderson C, Bond C, Fortnum H, Gifford A, Hannaford P, Hazell L, Krska J, Lee A, McLernon D, et al. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow card scheme': Literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1-234.
8. Aagaard L. Knowledge creation about adverse drug reactions in the paediatric population. Ugeskr Laeger. 2013;175(6):342-45.
9. Bate A, Evans S. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6): 427-36.
10. Ryan PB, Madigan D, Stang PE, Marc-Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401-15.
11. Reps JM, Garibaldi JM, Aickelin U, Soria D, Gibson J, Hubbard R. Comparison of algorithms that detect drug side effects using electronic healthcare databases. Soft Comput. 2013;17(12): 2381-97. doi:10.1007/s00500-013- 1097-4.
12. Jin H, Chen J, He H, Kelman C, McAullay D, O'Keefe CM. Signaling potential adverse drug reactions from administrative health databases. IEEE Trans Knowl Data Eng. 2010;22(6): 839-53.
13. Simpson SE. Self-controlled methods for postmarketing drug safety surveillance in large-scale longitudinal data. Ph.D. thesis, Columbia University; 2011.
14. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6): 1010-21.
15. Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22(1):39-56.
16. Norén GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20(3):361-87.
17. Greenland S, Neutra R. Control of confounding in the assessment of medical technology. Int J Epidemiol. 1980;9(4):361-67. (Pubitemid 11167166)
18. Reps JM, Garibaldi JM, Aickelin U, Soria D, Gibson JE, Hubbard RB. A novel prescription drug side effect classifier. IEEE Trans Knowl Data Eng. 2014 (submitted)
19. Joint Formulary Committee. British National Formulary, 66 ed. London: BMJ Group and Pharmaceutical Press; 2013.
20. Liaw A, Wiener M. Classification and regression by random forest. R News. 2002;2(3):18-22. http://CRAN.R-project.org/doc/Rnews/
21. Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inf Assoc. 2012;19(1):54-60.